It killed around 97,000 women in the same year. Imfinzi is currently approved for lung and biliary tract tumours, while Lynparza is used to treat ovarian, breast, pancreatic, and prostate cancer.

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseases. While th ...